+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
P

Actively Recruiting

Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.

Age: 45Years +All GendersPhase 3
231 locations
E

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the Advance Evero18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter Evero drug-coated balloon, DCB compared to paclitaxel drug-coated balloons in patients with peripheral arterial disease PAD affecting the femoropopliteal artery. The study is a randomized controlled trial designed to demonstrate that the Evero DCB is not inferior in safety and effectiveness to commercially available paclitaxel DCBs. Participants will be treated with either the Evero DCB or a commercially available paclitaxel-coated balloon to provide local treatment to de novo or restenotic lesions in the native superficial femoral and popliteal arteries. The treatments involve percutaneous transluminal angioplasty PTA using these drug-coated balloons applied directly to the affected arteries. During the study, participants will be monitored for safety endpoints such as death within 30 days, and amputation or clinically driven target lesion revascularization CD-TLR within 12 months. Effectiveness will also be evaluated at 12 months. Participants will undergo follow-up assessments according to the study schedule to measure these outcomes, with the trial expected to complete by October 2032.

Age: 18Years +All GendersPhase Not Applicable
15 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the FastWire System in patients who have chronic total occlusions CTOs in the arteries of their lower limbs. This study focuses on patients with severe leg ischemia caused by these blockages, aiming to see if the FastWire System can help place guidewires or treatment devices through these total artery blockages. The trial is a single-arm, multi-center pivotal study involving up to 65 participants with specific artery conditions. Participants will undergo treatment using the FastWire System, a device intended to assist during the procedure by crossing chronic total occlusion caps or multiple lesions in the peripheral arteries below the superficial femoral artery. The treatment is performed during a single procedure, with the goal of facilitating intra-luminal placement of wires or devices through the blocked arteries. This is an interventional study focused on treatment with no comparison group. During the study, participants will be monitored closely on the day of the procedure and up to 30 days afterward. Researchers will evaluate clinical and technical success on the procedure day, freedom from serious adverse events up to 30 days, vessel dissection or bleeding shortly after the procedure, and procedure-related mortality within 7 and 30 days. Participants will have assessments related to safety and effectiveness, including imaging and clinical evaluations, to measure the outcomes of the FastWire System treatment.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
6 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
R

Actively Recruiting

Researchers are conducting an observational study called XLPAD to evaluate the effectiveness and use of stent and non-stent therapies among patients with peripheral arterial disease PAD. This study aims to create a registry including data from procedures and clinical follow-ups, collecting information from patients treated since January 1, 2005, until 14,000 patients are enrolled. The study focuses on comparing outcomes like need for revascularization, surgical interventions, amputations, and safety events such as death, heart attack, stroke, and procedural complications over 12 months. Patients who receive endovascular interventions involving stents or percutaneous transluminal angioplasty PTA in specific leg arteries, including superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries, will be included. The study collects detailed background, lesion, intervention, and outcome data into an online system called REDCAP. Follow-up data is gathered at 6 and 12 months after the procedure, but follow-up visits are based on usual clinical care and not mandated by the registry. Treatment decisions, including use of stents or other therapies, remain at the discretion of the care team. Participants contribute by allowing the collection of their medical records, procedural details, and follow-up information. Data collected include patient characteristics, lesion features, treatment details, and clinical outcomes like walking distance and ankle-brachial index changes. Researchers will review events and outcomes up to 12 months post-procedure to assess treatment effectiveness and safety. The registry poses minimal risk since it observes routine care without altering treatments. Total participation duration depends on clinical follow-up timing, typically up to one year after the initial intervention.

All AgesAll Genders
24 locations
M

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a sirolimus drug coated balloon compared to standard balloon angioplasty for treating below the knee arterial disease. This pivotal, prospective, randomized, two-arm, placebo-controlled trial will be conducted at about 80 sites worldwide, including the USA, Europe, Australia, and Asia. The study addresses the high burden of limb loss caused by peripheral arterial disease and explores sirolimus as an alternative to paclitaxel for drug coated balloons below the knee. Participants will be randomly assigned in equal groups to receive either the MagicTouch PTA sirolimus coated balloon catheter plus standard balloon angioplasty or a placebo balloon angioplasty plus standard balloon angioplasty. All patients first receive pre-dilation with a standard balloon angioplasty. The sirolimus coated balloon is used as an additional treatment after successful lesion preparation. The trial is single-blind and multicenter, aiming to compare outcomes between these two treated groups. During the study, participants will undergo assessments including angiographic evaluations and monitoring of limb health. The primary outcome is primary patency at 12 months, defined by freedom from vessel occlusion, restenosis, target lesion revascularization, and major amputation. Safety will also be evaluated at 6 months and 30 days with composite endpoints. Secondary outcomes include various safety and efficacy measurements up to 60 months. This comprehensive follow-up will help assess long-term treatment effects and participant safety throughout the study period.

Age: 21Years +All GendersPhase Not Applicable
29 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations

1-10 of 11

1